In the United States,<unk>  is the fourth most common type of cancer among women. Development of<unk>  is the result of multiple genetic mutations. Genes involved in the pathogenesis of<unk>  include TP53, KRAS, and PTEN. Approximately 8–30% of patients with atypical<unk>  hyperplasia may progress to develop<unk> . The pathophysiology of<unk>  depends on the 7 histological subtypes: endometrioid, uterine papillary serous, mucinous,  clear cell, squamous cell, mixed and undifferentiated. Common risk factors in the development of<unk>  are estrogen exposure, tamoxifen, obesity, diabetes, high blood pressure and genetic disorders. The hallmark of<unk>  is abnormal vaginal bleeding. A positive history of bleeding between normal periods in premenopausal women and vaginal bleeding and/or spotting in postmenopausal women is suggestive of<unk> . Pelvic MRI and<unk>  biopsy may be diagnostic of<unk> . Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good. The optimal therapy for<unk>  depends on the stage at diagnosis and comprises total hysterectomy and bilateral salpingo-oophorectomy to most patients if they are surgical candidates.
Endometrial cancer
Cervical cancer
Uterine cancer
Ovarian cancer
Vaginal cancer
Breast-ovarian cancer
Breast cancer
Intravenous leiomyomatosis